Metoject

Methotrexate, the active ingredient in Metoject, is an antimetabolite presented as an injection for intramuscular, intravenous, and subcutaneous use. It is employed in the management of several autoimmune and oncologic conditions, including rheumatoid arthritis, psoriasis, and certain cancers.

GNH USA supplies Metoject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Metoject is an antimetabolite used across a range of autoimmune and malignant disease pathways. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: diminishes skin plaque formation and severity. - Acute lymphoblastic leukemia: interferes with malignant cell proliferation. - Non‑Hodgkin lymphoma: impedes growth of lymphoma cells. - Gestational trophoblastic disease: promotes resolution of abnormal trophoblastic tissue.

Metoject may cause a range of adverse reactions.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Fatigue: general tiredness or lack of energy. - Mouth sores: ulceration of oral mucosa. - Elevated liver enzymes: mild hepatic enzyme changes.

Serious or Rare Side Effects: - Bone marrow suppression: risk of anemia, leukopenia, or thrombocytopenia. - Severe hepatotoxicity: potential for liver injury requiring monitoring. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Renal impairment: reduced kidney function, especially with high doses.

Before initiating Metoject, several safety considerations are recommended. - Monitor blood counts: perform regular CBC to detect marrow suppression. - Assess liver function: check transaminases and bilirubin periodically. - Evaluate renal function: ensure adequate clearance before dosing. - Avoid use in pregnancy: teratogenic risk requires strict contraception. - Counsel about contraception: both male and female patients must use effective methods. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several drug classes, requiring careful management.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Trimethoprim‑sulfamethoxazole: potentiates bone marrow suppression.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may raise methotrexate serum levels. - Penicillins (high‑dose): can reduce renal clearance of methotrexate. - Live vaccines: risk of infection due to immunosuppression.